Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013

Annals of Clinical Microbiology and Antimicrobials

Volumn 14, Issue 1, 2015, Pages

  Hoban, Daryl J ^a,c   Reinert, Ralf Rene ^b   Bouchillon, Samuel K ^c   Dowzicky, Michael J ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PFIZER INC   (United States)

^c Division of Microbiology   (United States)

Author keywords

Antimicrobial drug resistance; Gram negative bacteria; Gram positive bacteria; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA OXYTOCA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; BACTERIUM; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; EPIDEMIOLOGICAL MONITORING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG EVALUATION; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 84929623837     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-015-0085-1     Document Type: Article

References (25)

1. Choudhury R, Panda S, Singh DV. Emergence and dissemination of antibiotic resistance: A global problem. Indian J Med Microbiol. 2012;30:384-90.
2. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439-48.
3. Lagacé-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ, et al. Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. J Antimicrob Chemother. 2013;68 Suppl 1:i23-9.
4. Saidel-Odes L, Borer A. Limiting and controlling carbapenem-resistant Klebsiella pneumoniae. Infect Drug Resist. 2013;7:9-14.
5. Grau S, Bou G, Fondevilla E, Nicolás J, Rodríguez-Maresca M, Martínez-Martínez L. How to measure and monitor antimicrobial consumption and resistance. Enferm Infecc Microbiol Clin. 2013;31 Suppl 4:16-24.
6. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis. 2009;65:288-99.
7. Cattoir V, Dowzicky MJ. A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012. Antimicrob Resist Infect Control. 2014;3:36.
8. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard. Ninth edition. Document M7-A9. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2012.
9. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: Twenty-third edition. Document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2013.
10. Pfizer Inc. (Wyeth Pharmaceuticals). Tygacil® Product Insert. Philadelphia, PA; 2013 [ http://www.pfizerpro.com/hcp/tygacil ]
11. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control; 2013.
12. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis. 2013;56:1310-8.
13. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014;43:328-34.
14. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Biedenbach DJ, Cantón R, et al. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int J Antimicrob Agents. 2013;41:224-8.
15. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother. 2011;66:2070-4.
16. Sanchez GV, Master RN, Clark RB, Fyyaz M, Duvvuri P, Ekta G, et al. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998-2010. Emerg Infect Dis. 2013;19:133-6.
17. Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis. 2013;75:107-9.
18. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233-8.
19. Morfín-Otero R, Alcántar-Curiel MD, Rocha MJ, Alpuche-Aranda CM, Santos-Preciado JI, Gayosso-Vázquez C, et al. Acinetobacter baumannii infections in a tertiary care hospital in Mexico over the past 13 years. Chemotherapy. 2013;59:57-65.
20. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). Diagn Microbiol Infect Dis. 2013;75:417-22.
21. Sader HS, Farrell DJ, Flamm RK, Jones RN. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother. 2014;58:2274-80.
22. Hawser S. Surveillance programmes and antibiotic resistance: worldwide and regional monitoring of antibiotic resistance trends. Handb Exp Pharmacol. 2012;211:31-43.
23. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013;6:1335-46.
24. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682-707.
25. Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo- β-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013;62:499-513.